MassachusettsChildren Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Children are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Population Estimate Benchmark Distance to Benchmark
Adolescent males ages 13-15 who received 3 or more doses of human papillomavirus (HPV) vaccine Total 45.1 43.2 Achieved: 4% better
Children ages 19-35 months who received 4 or more doses of diphtheria-tetanus-pertussis vaccine Total 92.6 90.6 Achieved: 2% better
Children ages 19-35 months who received 1 or more doses of measles-mumps-rubella vaccine Total 98.3 96.4 Achieved: 2% better
Children ages 19-35 months who received 1 or more doses of varicella vaccine Total 97.6 95.7 Achieved: 2% better
Adolescents ages 13-15 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years Total 96.4 95.2 Achieved: 1% better
Adolescents ages 16-17 who received 1 or more doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of ten years Total 95.8 95.9 0.1%
Adolescents ages 13-15 who received 1 or more doses of meningococcal conjugate vaccine Total 94.9 95.4 0.5%
Children ages 19-35 months who received 3 or more doses of polio vaccine Total 96.1 97.3 1.2%
Children ages 19-35 months who received 3 or more doses of hepatitis B vaccine Total 92.9 96.4 3.6%
Adolescents ages 16-17 who received 1 or more doses of meningococcal conjugate vaccine Total 92.5 96.2 3.8%
Measures That Are Close to Benchmark
Measure Population Estimate Benchmark Distance to Benchmark
Infants born in the calendar year who received breastfeeding exclusively through 3 months Total 47.7 63.6 25.0%
Measures With No Available Benchmark Information
Measure Population Estimate Benchmark Distance to Benchmark
Adolescents females ages 13-15 who received 3 or more doses human papillomavirus vaccine Total
Adolescents females ages 16-17 who received 3 or more doses human papillomavirus vaccine Total